Composition:
Each tablet of Lapatinib 250 mg contains 250 mg of Lapatinib as the active ingredient.
Description:
HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy. Lapatinib is used in combination with other medication Capecitabine or Letrozole, which together, inhibit the growth of cancer cells in patients.
Lapatinib 250 mg is mainly prescribed for the treatment of:
Share your experience with our medical product. Write a review!
15 Jul 2026
World Brain Tumor Day 2026: Early Detection Awareness and the Need to Reduce Diagnostic Delays
World Brain Tumor Day is observed annually on 8 June to raise awareness about brain tumours, encourage early diagnosis, and support patients and families affected by these complex conditions.
15 Jun 2026
Hetero Healthcare on World No Tobacco Day 2026 - Unmasking the Appeal, Countering Addiction
Every year on May 31, the world comes together to observe World No Tobacco Day, a global initiative aimed at raising awareness about the dangers of tobacco use.
01 Jun 2026
Salt, Stress, and Sedentary Life: The Three Big Triggers of Hypertension
Every two seconds, somewhere in the world, a person suffers a heart attack or stroke linked to uncontrolled blood pressure.
25 Apr 2026
World Liver Day 2026: Signs, Causes & How to Protect Your Liver Naturally
The liver is one of the most vital organs in the human body, responsible for detoxification, metabolism, and nutrient storage. Yet, liver health is often overlooked until symptoms become serious.
